Literature DB >> 22467877

Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor.

Erin E Cawston1, Polo C H Lam, Kaleeckal G Harikumar, Maoqing Dong, Alicja M Ball, Mary Lou Augustine, Eyup Akgün, Philip S Portoghese, Andrew Orry, Ruben Abagyan, Patrick M Sexton, Laurence J Miller.   

Abstract

Allosteric binding pockets in peptide-binding G protein-coupled receptors create opportunities for the development of small molecule drugs with substantial benefits over orthosteric ligands. To gain insights into molecular determinants for this pocket within type 1 and 2 cholecystokinin receptors (CCK1R and CCK2R), we prepared a series of receptor constructs in which six distinct residues in TM2, -3, -6, and -7 were reversed. Two novel iodinated CCK1R- and CCK2R-selective 1,4-benzodiazepine antagonists, differing only in stereochemistry at C3, were used. When all six residues within CCK1R were mutated to corresponding CCK2R residues, benzodiazepine selectivity was reversed, yet peptide binding selectivity was unaffected. Detailed analysis, including observations of gain of function, demonstrated that residues 6.51, 6.52, and 7.39 were most important for binding the CCK1R-selective ligand, whereas residues 2.61 and 7.39 were most important for binding CCK2R-selective ligand, although the effect of substitution of residue 2.61 was likely indirect. Ligand-guided homology modeling was applied to wild type receptors and those reversing benzodiazepine binding selectivity. The models had high predictive power in enriching known receptor-selective ligands from related decoys, indicating a high degree of precision in pocket definition. The benzodiazepines docked in similar poses in both receptors, with C3 urea substituents pointing upward, whereas different stereochemistry at C3 directed the C5 phenyl rings and N1 methyl groups into opposite orientations. The geometry of the binding pockets and specific interactions predicted for ligand docking in these models provide a molecular framework for understanding ligand selectivity at these receptor subtypes. Furthermore, the strong predictive power of these models suggests their usefulness in the discovery of lead compounds and in drug development programs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467877      PMCID: PMC3365725          DOI: 10.1074/jbc.M111.335646

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Pocketome via comprehensive identification and classification of ligand binding envelopes.

Authors:  Jianghong An; Maxim Totrov; Ruben Abagyan
Journal:  Mol Cell Proteomics       Date:  2005-03-09       Impact factor: 5.911

2.  Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.

Authors:  Kaleeckal G Harikumar; Delia I Pinon; Laurence J Miller
Journal:  J Biol Chem       Date:  2006-07-20       Impact factor: 5.157

3.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

Review 4.  Cholecystokinin and gastrin receptors.

Authors:  Marlène Dufresne; Catherine Seva; Daniel Fourmy
Journal:  Physiol Rev       Date:  2006-07       Impact factor: 37.312

5.  Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation.

Authors:  E M Hadac; D V Ghanekar; E L Holicky; D I Pinon; R W Dougherty; L J Miller
Journal:  Pancreas       Date:  1996-08       Impact factor: 3.327

6.  Homology modeling by the ICM method.

Authors:  T Cardozo; M Totrov; R Abagyan
Journal:  Proteins       Date:  1995-11

7.  Direct identification of the agonist binding site in the human brain cholecystokininB receptor.

Authors:  J Anders; M Blüggel; H E Meyer; R Kühne; A M ter Laak; E Kojro; F Fahrenholz
Journal:  Biochemistry       Date:  1999-05-11       Impact factor: 3.162

8.  Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.

Authors:  Elodie Archer-Lahlou; Irina Tikhonova; Chantal Escrieut; Marlène Dufresne; Catherine Seva; Lucien Pradayrol; Luis Moroder; Bernard Maigret; Daniel Fourmy
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

9.  Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.

Authors:  Maoqing Dong; Guangming Liu; Delia I Pinon; Laurence J Miller
Journal:  Biochemistry       Date:  2005-05-03       Impact factor: 3.162

10.  Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".

Authors:  C J Aquino; D R Armour; J M Berman; L S Birkemo; R A Carr; D K Croom; M Dezube; R W Dougherty; G N Ervin; M K Grizzle; J E Head; G C Hirst; M K James; M F Johnson; L J Miller; K L Queen; T J Rimele; D N Smith; E E Sugg
Journal:  J Med Chem       Date:  1996-01-19       Impact factor: 7.446

View more
  16 in total

1.  Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding.

Authors:  Maoqing Dong; Ashton M Vattelana; Polo C-H Lam; Andrew J Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; David R Haines; Laurence J Miller
Journal:  Mol Pharmacol       Date:  2014-10-15       Impact factor: 4.436

2.  Beneficial effects of β-sitosterol on type 1 cholecystokinin receptor dysfunction induced by elevated membrane cholesterol.

Authors:  Aditya J Desai; Maoqing Dong; Laurence J Miller
Journal:  Clin Nutr       Date:  2016-03-15       Impact factor: 7.324

Review 3.  Metabolic Actions of the Type 1 Cholecystokinin Receptor: Its Potential as a Therapeutic Target.

Authors:  Laurence J Miller; Aditya J Desai
Journal:  Trends Endocrinol Metab       Date:  2016-05-04       Impact factor: 12.015

4.  Impact of ursodeoxycholic acid on a CCK1R cholesterol-binding site may contribute to its positive effects in digestive function.

Authors:  Aditya J Desai; Maoqing Dong; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-02       Impact factor: 4.052

5.  Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity.

Authors:  Aditya J Desai; Brad R Henke; Laurence J Miller
Journal:  Bioorg Med Chem Lett       Date:  2015-03-24       Impact factor: 2.823

Review 6.  Cholecystokinin-induced satiety, a key gut servomechanism that is affected by the membrane microenvironment of this receptor.

Authors:  A J Desai; M Dong; K G Harikumar; L J Miller
Journal:  Int J Obes Suppl       Date:  2016-11-16

7.  Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex.

Authors:  Aditya J Desai; Polo C H Lam; Andrew Orry; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Med Chem       Date:  2015-12-10       Impact factor: 7.446

8.  Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.

Authors:  Maoqing Dong; Laurence J Miller
Journal:  Peptides       Date:  2013-06-14       Impact factor: 3.750

9.  Gastrin receptor pharmacology.

Authors:  Graham J Dockray; Andy Moore; Andrea Varro; D Mark Pritchard
Journal:  Curr Gastroenterol Rep       Date:  2012-12

10.  Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.

Authors:  Kaleeckal G Harikumar; Erin E Cawston; Polo C H Lam; Achyut Patil; Andrew Orry; Brad R Henke; Ruben Abagyan; Arthur Christopoulos; Patrick M Sexton; Laurence J Miller
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.